Clinical Trial Update: A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating the addition of nivolumab to cisplatin-based chemoradiation for squamous cell carcinoma of the head and neck.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• CISPLATIN (cisplatin)
• nivolumab (nivolumab)

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 3 | Status: ACTIVE_NOT_RECRUITING